Original Article

You have full text access to this OnlineOpen article

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta

  1. Nick Bishop1,2,*,
  2. Rachel Harrison2,
  3. Faisal Ahmed3,
  4. Nick Shaw4,
  5. Richard Eastell5,
  6. Mike Campbell6,
  7. Elizabeth Knowles1,2,
  8. Claire Hill2,
  9. Christine Hall7,
  10. Steve Chapman4,
  11. Alan Sprigg2,
  12. Alan Rigby8

Article first published online: 18 DEC 2009

DOI: 10.1359/jbmr.090712

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 32–40, January 2010

Additional Information

How to Cite

Bishop, N., Harrison, R., Ahmed, F., Shaw, N., Eastell, R., Campbell, M., Knowles, E., Hill, C., Hall, C., Chapman, S., Sprigg, A. and Rigby, A. (2010), A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res, 25: 32–40. doi: 10.1359/jbmr.090712

Author Information

  1. 1

    Academic Unit of Child Health, University of Sheffield

  2. 2

    Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdon

  3. 3

    Royal Hospital for Sick Children, Glasgow, United Kingdom

  4. 4

    Birmingham Children's NHS Foundation Trust, Birmingham, United Kingdom

  5. 5

    Academic Unit of Bone Metabolism

  6. 6

    ScHARR, University of Sheffield, Sheffield, United Kingdon

  7. 7

    Great Ormond Street Hospital for Children, London, United Kingdom

  8. 8

    University of Hull, Hull, United Kingdom

*University of Sheffield, Sheffield Childrens Hospital, Western Bank, Sheffield S12 3XW, United Kingdom.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 DEC 2009
  3. Manuscript Accepted: 1 JUL 2009
  4. Manuscript Revised: 29 APR 2009
  5. Manuscript Received: 30 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (119K)

References

  • 1
    Rauch F, Glorieux FH. Treatment of children with osteogenesis imperfecta. Curr Osteoporos Rep. 2006; 4: 159–164.
  • 2
    Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004; 363: 1427–1431.
  • 3
    Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005; 20: 977–986.
    Direct Link:
  • 4
    Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005; 20: 758–763.
    Direct Link:
  • 5
    Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005; 90: 4051–4056.
  • 6
    Kishimoto H, Fukunaga M, Kushida K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Res. 2006; 24: 405–413.
  • 7
    Francis RM. What do we currently know about nutrition and bone health in relation to United Kingdom public health policy with particular reference to calcium and vitamin D? Br J Nutr. 2008; 99: 155–159.
  • 8
    Kroger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. Bone Miner. 1992; 17: 75–85.
  • 9
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339: 947–952.
  • 10
    Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop. 1981; 159: 88–96.
  • 11
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11: 83–91.
  • 12
    Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007; 22: 142–148.
    Direct Link:
  • 13
    Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004; 34: 539–546.
  • 14
    Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003; 88: 986–992.
  • 15
    Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006; 39: 443–452.
  • 16
    Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002; 86: 356–364.
  • 17
    Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006; 39: 901–906.
  • 18
    Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 2007; 1117: 209–257.
    Direct Link:
View Full Article (HTML) Get PDF (119K)